Slate Run Pharmaceuticals recalls
FDA enforcement reports naming Slate Run Pharmaceuticals as the recalling firm.
- Recall reports
- 3
- Class I (serious)
- 0
- Most recent report
- Mar 4, 2026
- Mar 4, 2026Eptifibatide Injection, 75 mg/100 mL vial for weight-adjusted bolus dosing, 1x100 mL Si…Drug · Slate Run PharmaceuticalsLabeling: Not Elsewhere Classified. The carton for Eptifibatide Injection 75 mg/100 mL states 75 mg/100 mL vial for weight-adjusted bolus dosing. The approved statement is 75 mg/100 mL vial for weight-adjusted infusion.Class III
- Mar 26, 2025Cinacalcet Hydrochloride Tablets 30 mg, 30-count bottle, Rx only, DistrDrug · Slate Run PharmaceuticalsCGMP deviations: The presence of nitrosamine impurity above the acceptable daily intake limits.Class II
- Mar 26, 2025Cinacalcet Hydrochloride Tablets 60 mg, 30-count bottle, Rx only, DistrDrug · Slate Run PharmaceuticalsCGMP deviations: The presence of nitrosamine impurity above the acceptable daily intake limits.Class II